Carregant...
Efficacy of Ruxolitinib for Myelofibrosis
INTRODUCTION: The discovery of the activating JAK2V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to enter clinical trials was ruxolitinib. This review summarizes pre-clinical and clinical data of ruxolitinib in MF. AREAS COVERED...
Guardat en:
| Publicat a: | Expert Opin Pharmacother |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4824286/ https://ncbi.nlm.nih.gov/pubmed/24856675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2014.923404 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|